Aravive to Host Key Opinion Leader Symposium on May 11, 2022
May 05 2022 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology
company developing targeted therapeutics to treat metastatic
disease, today announced that it will host a Key Opinion Leader
(KOL) Symposium on the GAS6-AXL signaling pathway and the Company’s
lead drug candidate, batiraxcept. Senior management will also
provide updates on Aravive’s clinical development programs. The
event will take place on May 11, 2022, from 8:00 am ET to 12:00 pm
ET and will include a live and archived webcast at:
https://ir.aravive.com/events-and-presentations.
The anticipated KOL Symposium schedule (all times are ET):
- 8:50 am - 9:00 am Opening Remarks
- Gail McIntyre, Ph.D.; Aravive CEO and Director
- 9:00 am - 9:30 am Overview of the TAM Kinases:
- Amato Giaccia, Ph.D.; Aravive Founder and Director Director,
MRC Oxford Institute for Radiation Oncology Jack, Lulu and Sam
Wilson Professor of Radiation Oncology, Emeritus, Stanford
University
- 9:30 am - 10:00 am Batiraxcept in PROC:
- Katherine Fuh, M.D., Ph.D.; Gynecologic Oncologist &
Associate Professor Division of Gynecologic Oncology, Washington
University, Siteman Cancer Center
- 10:00 am - 10:30 am Batiraxcept in ccRCC:
- Brian Rini, M.D.; Chief of Clinical Trials, Vanderbilt-Ingram
Cancer Center & Professor of Medicine, Division of
Hematology/Oncology, Vanderbilt University Medical Center
- 10:30 am - 11:00 am Batiraxcept in Pancreatic Adenocarcinoma:
- Paul Oberstein, M.D., M.S.; Associate Professor of Medicine and
Director of Gastrointestinal Medical Oncology, Perlmutter
Comprehensive Cancer Center, NYU Langone Health
- 11:00 am - 11:15 am Program Updates
- 11:15 am - 12:00 pm Panel Discussion and Q&A
About AraviveAravive, Inc. is a
late clinical-stage oncology company developing targeted
therapeutics to treat metastatic disease. Our lead product
candidate, batiraxcept (formerly AVB-500), is an ultra-high
affinity decoy protein that binds to GAS6, the sole ligand that
activates AXL, thereby inhibiting metastasis and tumor growth, and
restoring sensitivity to anti-cancer agents. Batiraxcept has been
granted Fast Track Designation by the U.S. FDA and Orphan Drug
Designation by the European Commission in platinum-resistant
recurrent ovarian cancer. Batiraxcept is in an active
registrational Phase 3 trial in platinum resistant ovarian cancer
(NCT04729608), a Phase 1b/2 trial in clear cell renal cell
carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic
adenocarcinoma (NCT04983407). The Company is based in Houston,
Texas and received a Product Development Award from the Cancer
Prevention & Research Institute of Texas (CPRIT) in 2016.
Additional information at www.aravive.com.
Contact:Marek Ciszewski, J.D.Vice President,
Investor RelationsMarek@Aravive.com(562) 373-5787
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024